Combination therapy based on sonodynamic therapy (SDT) combined with immune checkpoint blockers anti-PD-L1 provides effective anti-tumor effects. We designed a combination therapy based on M1/PLGA@IR780/CAT NPs of SDT-enhanced immunity combined with immune checkpoint blockers against PD-L1, which was based on M1 macrophage membrane-encapsulated poly (lactic-co-glycolic acid) (PLGA) nanoparticles loaded with the acoustic sensitizer IR780 and catalase (CAT) to successfully realize it. SDT based on M1/PLGA@IR780/CAT NPs could induce tumor cell death by promoting dendritic cell (DC) maturation and modulating the tumor immune microenvironment. In particular, the systemic anti-tumor immune response and potent immune memory induced upon combination with anti-PD-L1 checkpoint blockade not only alleviated the progression of mammary cancer in 4T1 mice and effectively blocked distant metastasis, but also prevented tumor recurrence, providing a promising new therapeutic strategy for clinical tumor therapy.

基于声动力疗法（SDT）与免疫检查点阻断剂抗PD-L1的联合治疗可提供有效的抗肿瘤作用。我们设计了一种基于SDT增强免疫的M1/PLGA@IR780/CAT NPs联合针对PD-L1的免疫检查点阻断剂的联合疗法，该疗法以M1巨噬细胞膜包裹的聚乳酸乙醇酸（PLGA）为基础。 ）纳米颗粒负载声敏剂IR780和过氧化氢酶（CAT）成功实现了这一点。基于M1/PLGA@IR780/CAT NPs的SDT可以通过促进树突状细胞（DC）成熟和调节肿瘤免疫微环境来诱导肿瘤细胞死亡。特别是，与抗PD-L1检查点阻断联合诱导的全身抗肿瘤免疫反应和有效的免疫记忆，不仅减轻了4T1小鼠乳腺癌的进展，有效阻断远处转移，而且还预防了肿瘤复发，为4T1小鼠提供了新的治疗方案。临床肿瘤治疗有前景的新治疗策略。